MannKind (MNKD)
(Delayed Data from NSDQ)
$4.23 USD
+0.05 (1.20%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.22 -0.01 (-0.24%) 5:18 PM ET
2-Buy of 5 2
C Value A Growth F Momentum C VGM
MannKind (MNKD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.08 | $10.00 | $5.00 | 69.38% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for MannKind comes to $7.08. The forecasts range from a low of $5.00 to a high of $10.00. The average price target represents an increase of 69.38% from the last closing price of $4.18.
Analyst Price Targets (6 )
Broker Rating
MannKind currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/15/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Strong Buy |
2/28/2024 | Wedbush Securities | Andreas Argyrides | Strong Buy | Strong Buy |
1/4/2024 | H.C. Wainwright & Co. | Oren Livnat | Strong Buy | Strong Buy |
11/8/2023 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 6 |
Average Target Price | $7.08 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | 0.02 |